Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials

M. López-Fauqued, J.E. McElhaney, S.A. McNeil, W. Yeo, F. Tavares-Da-Silva, A. Ahonen, T.J. Avelino-Silva, J.F. Barba-Gomez, J. Berglund, C.B. Cuixart, C. Caso, L. Campora, R. Chlibek, W.S. Choi, A.L. Cunningham, M.G. Desole, P. Eizenberg, M. Esen, E. Espié, P. GervaisW. Ghesquiere, O. Godeaux, F. Delannois, I. Gorfinkel, D.S.C. Hui, S.-J. Hwang, T. Korhonen, M. Kovac, E. Ledent, E. Leung, M.J. Levin, S.N. Perez, J.L. Neto, M. El Idrissi, K. Pauksens, A. Poder, M.L.R. de la Pinta, Timo Vesikari, L. Oostvogels, F.J. De Looze, J. Diez-Domingo, T.C. Heineman, H. Lal

Research output: Contribution to journalArticleScientificpeer-review

11 Citations (Scopus)
Original languageEnglish
Pages (from-to)2482-2493
JournalVACCINE
Volume37
Issue number18
DOIs
Publication statusPublished - 2019
Publication typeA1 Journal article-refereed

Keywords

  • Reactogenicity
  • Safety
  • Vaccine
  • Varicella-zoster virus

Publication forum classification

  • Publication forum level 1

Cite this